Effect of HLA-matching recipients to donor non-inherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy, Biology of Blood and Marrow Transplantation (2012), doi: 10.1016/j.bbmt.2012 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 32% at 5 years after transplantation). Consequently, overall survival was higher after NIMA-matched transplantations. The 5-year probabilities of overall survival after NIMA-matched and NIMA-mismatched transplantations were 55% and 38%, respectively (p=0.04). When faced with the choice of multiple HLA-mismatched UCB units containing adequate cell dose, selecting a NIMA-matched UCB unit may improve survival after mismatched UCB transplantation.
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INTRODUCTION
Umbilical cord blood (UCB) is an acceptable graft choice when considering unrelated donor transplantation for patients with hematologic malignancies. In the United States, UCB grafts are used for about 20% of unrelated donor transplantations for hematologic malignancies and in Europe, for about 12%. We and others have shown similar leukemia-free survival despite higher transplant-related mortality (TRM) after transplantation of UCB compared to transplantation of HLA-matched bone marrow or peripheral blood progenitor cells from unrelated adult donors in children and adults with leukemia. 1, 2 High TRM after UCB transplantation remains a significant limitation and can be attributed to multiple factors. Some of the excess TRM after UCB transplantation results from infusion of units containing a relatively low total nucleated cell (TNC) dose.
The accepted standard now is to use a UCB unit that contains a minimum precryopreserved TNC of 3 x 10 7 /kilogram patient body weight and others recommend an incremental increase in TNC to overcome the HLA-barrier. 3, 4 When such a unit is lacking, the co-infusion of two un-manipulated UCB units is used to deliver higher TNC doses. 4, 5 Infusion of expanded hematopoietic progenitor cells with a single UCB unit is also employed to deliver higher TNC doses. 6, 7 Avoiding UCB units to which donor specific anti-HLA antibodies are present in the recipient lowers graft failure and mortality risks. [8] [9] [10] The importance of better donor-recipient HLA-matching for unrelated adult donor transplantation is clear. 11 Best results are obtained with an unrelated adult donor allele-matched to the recipient at HLA-A, -B, -C and -DRB1. Matching the UCB unit to the recipient at the HLA-C locus is associated with lower TRM.
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HLA-matching at HLA-A, -B and -C remains to be determined in the setting of UCB transplantation.
Two independent clinical studies done a decade apart, 13 17 NIMA-matched transplants were not associated with transplant-related or overall mortality even though both analyses were performed on largely the same cohort of donor-recipient pairs. As the majority of UCB transplants are mismatched and TRM a barrier to successful outcome, the current analysis was undertaken in an independent cohort of patients to determine whether matching the recipient to the UCB's non-inherited maternal antigen (i.e., NIMA) as reported by van Rood and colleagues 16 would indeed lower some of the excess mortality associated with mismatched UCB transplants.
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METHODS
Data Collection
The study includes patients reported to Eurocord-European Group for Blood and Table 1 .
Outcomes
TRM was defined as the time from transplantation to death not related to disease recurrence or progression and overall mortality defined as death from any cause.
Neutrophil recovery was defined as achieving an absolute neutrophil count ≥0.5 x 10 9 /L for three consecutive measurements on different days; grade 2-4 acute 18 and chronic 19 graft-versus-host disease (GVHD) based on reports using standard criteria from each transplant center; disease recurrence based on morphological evaluation supported by reappearance of abnormalities in cytogenetic or molecular analyses.
Statistical methods
The probabilities of TRM, recurrent disease, neutrophil recovery and acute and chronic GVHD were calculated using the cumulative incidence estimator to accommodate competing risks. 20 The probability of overall survival was calculated using the Kaplan-
Meier estimator. 20 95% confidence intervals (CI) were calculated with log transformation.
To assess the association between clinical outcomes and NIMA matching, cases (NIMAmatched) were matched to controls (NIMA-mismatched). A matched-pair analysis was considered appropriate given the relatively low frequency of NIMA-matched transplantations (8.5%). Prior to matching cases to controls, we built multivariate Cox regression model for TRM using patients that met the study eligibility (n=508). 21 Results are expressed as relative risk (RR). The characteristics of this cohort are shown in Supplemental Analyses were performed for the overall population and the Caucasian subset.
RESULTS
Patient, disease and transplant characteristics
Characteristics of cases and controls are shown in Table 2 . Seventy-five percent of patients were 16 years or younger at transplantation, 52%, male sex and 46% were CMV 
Transplant-related and overall mortality
The risk of TRM was lower after NIMA-matched compared to NIMA-mismatched transplantations (RR 0.48 95% CI 0.23 -1.01, p=0.05; Figure 1A ). Similarly, overall mortality risks were also lower after NIMA-matched compared to NIMA-mismatched transplantations (RR 0.61 95% CI 0.38 -0.98, p=0.04; Figure 1B ). Data on infections that occurred in the first 100 days after transplantation were available for 113 of 164
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(69%) transplants. The day-30 cumulative incidence of infections was 15% and 27%
after NIMA-matched and NIMA-mismatched transplants (p=0.24). The corresponding day-100 cumulative incidence at day-100 was 48% and 50%. Six of 20 (30%) deaths after NIMA-matched transplantations were attributed to TRM. Most of these deaths (4 of 6) occurred within 6 months after transplantation (n=2 multi-organ failure, n=1 infection, n=1 hemorrhage). Two deaths occurred beyond 6 months, one from infection and the other from chronic GVHD. Thirty-one of 66 (47%) deaths after NIMA-mismatched transplantations were attributed to TRM. Twenty-three of the 31 deaths occurred within 6 months after transplantation (n=6 multi-organ failure, n=8 infection, n=4 adult respiratory distress syndrome/interstitial pneumonitis, n=2 diffuse alveolar hemorrhage, n=1 Epstein Barr virus post-transplant lymphoproliferative disease; cause of death was not reported for two patients). Eight deaths occurred beyond 6 months (n=2 chronic GVHD, n=3 infection, n=2 multi-organ failure; cause of death was not reported for 1 patient).
Relapse
Relapse risks after NIMA-matched and NIMA-mismatched transplants were not different (RR 0.82 95% CI 0.47 -1.43, p=0.47). The 5-year probabilities of relapse were 31% (95% CI 18% -44%) after NIMA-matched transplantations and 33% (95% CI 24% -42%) after NIMA-mismatched transplantations.
The influence of antigen frequency on NIMA matching
The frequencies of NIMA-matched and NIMA-mismatched antigens/alleles were evaluated for the U.S cohort (N=429). Transplantations in Europe were excluded because the race of cord blood units and recipients were not always available. The 
DISCUSSION
Our primary objective was to assess the effect of tolerance to NIMA and its effect on mortality after HLA-mismatched UCB transplantation. Tolerance to NIMA in renal transplantation is well documented. 13, 14 In contrast, tolerance to NIMA and its effect on survival after mismatched UCB transplant is by no means conclusive. 16, 17 To circumvent the relatively small sample of NIMA-matched transplantations we adopted a matchedpair analysis, matching recipients for factors that influence TRM and overall survival, which allowed us to perform a carefully controlled analysis. We observed marginally lower TRM and overall mortality after NIMA-matched compared to NIMA-mismatched transplantations. This is consistent with the earlier report on the impact of NIMAs in M A N U S C R I P T
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13 UCB transplantation. 16 We hypothesize, allowing for permissive mismatching between UCB unit and the recipient lowered some of the excess mortality associated with HLAmismatched UCB transplantation. But the exact mechanism by which mortality is reduced is not easily explained. Higher survival after NIMA-matched transplants is likely to have been mediated by multiple factors such as better hematopoietic recovery, lower acute GVHD, lower rate of infections in the early post-transplant period and better immune reconstitution which together contributed to the observed survival advantage.
Unlike reports after haplo-identical transplantations, 23 we failed to see significant differences in acute or chronic GVHD rates after NIMA-matched and NIMA-mismatched UCB transplantations. Acute and chronic GVHD rates after UCB transplants are substantially lower than after haplo-identical transplants; as only about 10% of mismatched UCB transplants are NIMA-matched, several hundreds of patients are needed before we can conclude whether there are differences in GVHD rates after NIMA-matched and NIMA-mismatched transplantations.
Better HLA-matching of donors and recipients is associated with better hematopoietic recovery and consequently lower early mortality. In the current analysis, there is a 12% difference in the probability of neutrophil recovery after NIMA-matched and NIMAmismatched transplants. Our inability to detect a statistically significant difference can be explained by the small sample size and the ensuing wide confidence intervals of probability estimates. Further, the use of UCB units with relatively high TNC (>3 x 10 7 /kg) may have also lessened the importance of NIMA-matching for neutrophil recovery as has been shown to be the case with HLA-mismatched UCB transplants. 3, 24 Consistent with our findings, reports on tolerance to NIMAs after haplo-identical M A N U S C R I P T
14 transplantations where very high cell doses are used have also failed to show an association between NIMA-matching and neutrophil recovery. 23, 25 It is noteworthy that most deaths from transplant-related complications occurred within six months from transplantation. There may be differences in immune reconstitution after NIMA-matched and NIMA-mismatched transplants, a hypothesis we cannot test in this population. We used data reported to transplant registries and data on immune reconstitution are not available.
NIMA-matched transplants account for less than 10% of UCB transplants.
Incorporating NIMA-matching in an algorithm for UCB unit selection is complex and population. Therefore, searching for a NIMA-matched UCB unit would best be facilitated by selecting a mismatched UCB unit where the mismatch is a high frequency HLAantigen within the target population, such as HLA A*02 in Caucasians. 21 However, to truly understand the probability of finding a NIMA-match within a given population will require either complex mathematical models based on HLA haplotype frequencies or the addition of maternal HLA typing to UCB unit registries. Consultation with an HLA expert at search may allow physicians apply the surrogate approach described above to M A N U S C R I P T
15 identify a potential NIMA-matched UCB unit and request donor maternal HLA typing at time of confirmatory HLA typing of the UCB unit. The additional request for maternal HLA typing to those banks that do not routinely perform maternal HLA typing will add to their financial burden.
Taken together, the current analysis and the earlier report 16 
